Role of terminal warm blood cardioplegia in complex congenital heart surgery

Abstract

Introduction

Myocardial protection is vital to ensure successful open heart surgery. Cardioplegic solution is one method to achieve good myocardial protection. Inevitably, ischemia-reperfusion injury occurs with aortic crossclamping. Histidine-tryptophan-ketoglutarate solution is a frequently used cardioplegia for complex congenital heart surgery. We postulated that addition of terminal warm blood cardioplegia before removal of the aortic crossclamp might improve myocardial protection.

Method

A randomized controlled trial was conducted on 109 cyanotic patients aged, 1 to 5 years who underwent complex biventricular repair. They were divided into a control group of 55 patients who had histidine-tryptophan-ketoglutarate only and a treatment group of 54 who had histidine-tryptophan-ketoglutarate with terminal warm blood cardioplegia. Endpoints were clinical parameters, troponin I levels, and caspase-3 as an apoptosis marker.

Results

The incidence of low cardiac output syndrome was 34%, with no significant difference between groups (35.2% vs. 33.3%, p = 0.84). The incidence of arrhythmias in our treatment group was lower compared to the control group (36% vs. 12%, p = 0.005). Troponin I and caspase-3 results did not show any significant differences between groups. For cases with Aristotle score ≥ 10, weak expression of caspase-3 in the treatment group post-cardiopulmonary bypass was lower compared to the control group.

Conclusion

For complex congenital cardiac surgery, the addition of terminal warm blood cardioplegia does not significantly improve postoperative clinical or metabolic markers.

Keywords

Cardiopulmonary bypass Cardioplegic solutions Caspase 3 Heart arrest induced Heart defects congenital Myocardial reperfusion injury

Get full access to this article

View all access options for this article.

References

Soares

Ribas

Spring

et al.

Clinical profile of systemic inflammatory response after pediatric cardiac surgery with cardiopulmonary bypass. Arq Bras Cardiol 2010; 94: 127–133.

Lacour-Gayet

Clarke

Jacobs

et al.

The Aristotle score for congenital heart surgery. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004; 7: 185–191.

Sanada

Komuro

Kitakaze

. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 2011; 301: H1723–H1741.

Gauvreau

Allan

. Causes of death after congenital heart surgery. Ann Thorac Surg 2007; 83: 1438–1445.

Fischer

Tossios

Huebner

et al.

Myocardial apoptosis prevention by radical scavenging in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2004; 128: 103–108.

Eefting

Rensing

Wigman

. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004; 61: 414–426.

Black

Huang

Rezaiefar

. Co-localization of the cysteine protease caspase-3 with apoptotic myocytes after in vivo myocardial ischemia and reperfusion in the rat. J Mol Cell Cardiol 1998; 30: 733–742.

Ramlawi

Feng

Mieno

. Indices of apoptosis activation after blood cardioplegia and cardiopulmonary bypass. Circulation 2006; 114(Suppl I): I257–263.

Doenst

Schlensak

Beyersdorf

. Cardioplegia in pediatric cardiac surgery: do we believe in magic? Ann Thorac Surg 2003; 75: 1668–1677.

10.

Bojan

Peperstraete

Lilot

Tourneur

Vouhé

Pouard

. Cold histidine-tryptophan-ketoglutarate solution and repeated oxygenated warm blood cardioplegia in neonates with arterial switch operation. Ann Thorac Surg 2013; 95: 1390–1396.

11.

Habertheuer

Kocher

Laufer

et al.

Cardioprotection: a review of current practice in global ischemia and future translational perspective. Biomed Res Int 2014 2014; 2014: 325725–325725.

12.

Turkoz

. Myocardial protection in pediatric cardiac surgery. Artif Organs 2013; 37: 16–20.

13.

Liu

Feng

Zhao

et al.

The myocardial protection of HTK cardioplegic solution on the long-term ischemic period in pediatric heart surgery. ASAIO J 2008; 54: 470–473.

14.

Pouard

Mauriat

et al.

Normothermic cardiopulmonary bypass and myocardial cardioplegic protection for neonatal arterial switch operation. Eur J Cardiothorac Surg 2006; 30: 695–699.

15.

Ascione

Suleiman

Angelini

. Retrograde hot-shot cardioplegia in patients with left ventricular hypertrophy undergoing aortic valve replacement. Ann Thorac Surg 2008; 85: 454–458.

16.

Kotani

Tweddell

Gruber

et al.

Current cardioplegia practice in pediatric cardiac surgery: a North American multiinstitutional survey. Ann Thorac Surg 2013; 96: 923–929.

17.

Toyoda

Yamaguchi

Yoshimura

et al.

Cardioprotective effects and the mechanisms of terminal warm blood cardioplegia in pediatric cardiac surgery. J Thorac Cardiovasc Surg 2003; 125: 1242–1251.

18.

Kronon

Allen

Rahman

et al.

Reducing postischemic reperfusion damage in neonates using a terminal warm substrate-enriched blood cardioplegic reperfusate. Ann Thorac Surg 2000; 70: 765–770.

19.

Chandler

Kirsch

. Management of the low cardiac output syndrome following surgery for congenital heart disease. Curr Cardiol Rev 2016; 12: 107–111.

20.

Scarabelli

Pasini

Ferrari

et al.

Warm blood cardioplegic arrest induces mitochondrial-mediated cardiomyocyte apoptosis associated with increased urocortin expression in viable cells. J Thorac Cardiovasc Surg 2004; 128: 364–371.